Buprenorphine is one of three medications (methadone and naltrexone being the other two) approved for use to treat opioid use disorder. It is available as a film or tablet, and more recently as two long-acting extended-release injectables. Sublocade™ was first to be approved by the FDA in November 2017. More recently, in May 2023, Brixadi™ received approval. In January 2024 it was added to the WA state Medicaid formulary. Fewer clinicians have experience using Brixadi™ than Sublocade™. The CTN Pacific Northwest Node recently developed a set of videos intended to aid prescribers in their conversations with patients interested in these buprenorphine options, and have now added two new factsheets too: Injectable Buprenorphine: Getting Started Injectable Buprenorphine: Logistical Info for Clinics Find the complete set of resources here!

Join the CTN Youth SIG for their next webinar, “Age, Period, and Cohort Effects in Alcohol and Other Substance Use: Implications for Health and Prevention,” presented by Katherine M. Keyes, PhD (Columbia University), on Friday, January 17, 2025, 11am-12pm ET. Incidence, prevalence, and persistence of substance use differ by generation and by substance. Understanding how each generation uses alcohol and other drugs, why, and how health is implicated is critical for public health. The presentation will overview what we know about current trends in substance use, how rates are organized by age, period, and cohort, and how these trends are shaping public health overall. About the presenter Katherine M. Keyes, PhD, is Professor of Epidemiology at the Columbia University Mailman School of Public Health. Dr. Keyes’ research focuses on psychiatric and substance use epidemiologyacross the life course, including early and cross-generational origins of child and adult health and cohort effects on substance use, mental health, and injury outcomes including suicide and overdose. She is the author of more than 450 peer-reviewed publications, and two textbooks. Register here!

A recording of this webinar, held on November 20, 2024, is now available! (passcode: N7A3h^SX) Presenter:Dr. Curt LanglotzProfessor of Radiology, Medicine, and Biomedical Data ScienceSenior Associate Vice Provost for ResearchDirector, Center for Artificial Intelligence in Medicine & ImagingSenior Fellow, Institute for Human-Centered Artificial Intelligence Artificial intelligence (AI) is an incredibly powerful tool for building systems that support the work of clinicians and researchers. Over the last decade, machine learning methods have revolutionized the analysis of medical data, leading to high interest and explosive growth in the use of AI and machine learning methods. These promising techniques create systems that perform some clinical tasks at the level of expert physicians. Deep learning methods in imaging are now being developed for image reconstruction, imaging quality assurance, imaging triage, computer-aided detection, computer-aided classification, and radiology report drafting.  The systems have the potential to provide real-time assistance to radiologists and other imaging professionals, thereby reducing diagnostic errors, improving patient outcomes, and reducing costs.  We will review the origins of AI and its applications to medicine, and medical imaging, define key terms, and show examples of real-world applications that suggest how AI may change the practice of medicine.  We will also review key shortcomings and challenges that may limit the application of these new methods. About the presenter Curtis P. Langlotz, MD, PhD : Dr. Langlotz is Professor of Radiology, Medicine, and Biomedical Data Science, and Senior Associate Vice Provost for Research at Stanford University. His NIH-funded laboratory develops machine learning methods to improve the accuracy and…

The NIDA Office of Research Training, Diversity, and Disparities (ORTDD) is excited to share that the 2025 NIDA Diversity Scholars Network (NDSN) program is now accepting applications!  The deadline to apply is January 31, 2025! NIDA is seeking applications from individuals from diverse backgrounds, including those from underrepresented groups, who are interested in conducting substance use and addiction research. The NDSN is a grant-writing program aimed at enhancing the funding success of early-stage investigators. The program consists of three workshops and culminates in a mock review meeting experience. Questions? Contact Isabela Ellenwood (NDSN@nih.gov). Learn more and apply here!